Precision Therapeutics, Inc. Release: New Study Shows Association Between ChemoFx® Results and Recurrence Free Survival

PITTSBURGH--(BUSINESS WIRE)--A new study reporting an association between ChemoFx® Drug Response Marker results and recurrence free survival (RFS) of cervical cancer patients was presented at the 14th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), held in Vancouver October 13-16, 2012.
MORE ON THIS TOPIC